You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Targeting the host response to limit infection by intracellular bacterial pathogens

    SBC: Blue Ridge Biosciences, LLC            Topic: NIAID

    Antibiotic development has traditionally focused on drugs that target the pathogen but resistance inevitably developsAn attractive alternative is to develop drugs that target the host response and in particular for facultative obligate intracellular bacterial pathogenswhich rely on the host for disease progressionIntracellular bacterial pathogens manipulate the host cytoskeletal system to their ad ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Targeting TLR4-lipid rafts to prevent postoperative pain

    SBC: RAFT PHARMACEUTICALS LLC            Topic: 108

    PROJECT SUMMARY Postoperative pain is a prevalent source of pain requiring appropriate management to reduce its impact upon quality of life. Even with the availability of several analgesics, postoperative pain is often undermedicated because of concern related to the adverse consequence of the available therapeutics (e.g., NSAIDs and opiates), including addiction and decreased survival of cancer p ...

    STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Targets of Acquired Tick-Resistance As Anti-Tick Vaccines

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACTThis proposal seeks to develop a novel vaccine against pathogens transmitted by the blacklegged tick, Ixodes scapularis, by targeting tick salivary proteins (Salps) critical for tick feeding. I. scapularis Salps provide functions critical for evading host defense responses detrimental to the tick. Further, these salivary functions are also co-opted by tick-transmitted pathogens to ensure t ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  4. T cell cytokine assay for the diagnosis of disseminated Lyme borreliosis

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Lyme disease, due to infection with the Ixodes tick-transmitted spirochete Borrelia burgdorferi, is the most common vector-borne disease in the United States, with more than 28,000 cases reported annually. The infectioncan remain localized to the skin or disseminate to cause disease in the skin, heart, joints and nervous system. The ospC genotype of the spiroch ...

    STTR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. T CELL RECEPTOR AFFINITY VIA FREE ENERGY MINIMIZATION

    SBC: Pharmadyne, Inc.            Topic: N/A

    N/A

    STTR Phase I 1999 Department of Health and Human Services
  6. TeamChip for High-Throughput, Predictive Human Metabolism and Toxicology: Phase I

    SBC: Solidus Biosciences, Inc.            Topic: NIEHS

    DESCRIPTION (provided by applicant): Solidus Biosciences, Inc. in partnership with Rensselaer Polytechnic Institute, will focus on further development, validation, and commercialization of its proprietary Transfected Enzyme and Metabolism Chip (or TeamChip) for high-throughput analysis of systematic drug candidate and chemical metabolism and toxicology. The TeamChip is being developed to mimic ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Technology for Synthesis of Chemically Diverse RNAs

    SBC: BIOLYTIC LAB PERFORMANCE, INC.            Topic: 300

    Summary RNA synthesis technologies have become critical in basic biomedical research and in development of RNA based sensors diagnostics and therapeutics Currently RNAs are synthesized by either solid phase phosphoramidite chemistry or by transcription in solution with phage encoded RNA polymerases The structural diversity of chemically synthesized RNAs is limited by the availa ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practice

    SBC: BEAM Diagnostics, Inc.            Topic: 270

    PROJECT SUMMARY Alcohol use disorderAUDcontributes to excessive disabilitymorbidityand mortality in the United StatesAs one of the nation s leading preventable causes of deaththe first line of defense against AUD must be standardized screening provided by the patient s primary care physicianpsychiatristand or counselorStandardized screeninghoweveris simply under performedReform proposals call for ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Technology transfer of behavioral economic tasks for assessing alcohol reinforcer pathology: Development and feasibility of a commercially-available tool for clinical practice

    SBC: BEAM Diagnostics, Inc.            Topic: 270

    PROJECT SUMMARY Alcohol use disorder (AUD) contributes to excessive disability, morbidity, and mortality in the United States. As one of the nation’s leading causes of death, public health guidelines recommend consistent standardized alcohol screening. However, screening for alcohol misuse is underperformed, laborious, and is susceptible to demand characteristics and concerns about stigmatizing ...

    STTR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  10. Telomere homolog oligonucleotides for cancer therapy

    SBC: SEMACO, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Cancer is a devastating group of diseases, among the most common causes of death for Americans. Current therapies for advanced disease are highly toxic and all too often ineffective. Our group has recently demonstrated a powerful innate inducible ability of human cells to recognize and respond to damaged DNA, a characteristic of cancer cells. Moreover, we hav ...

    STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government